INMAZEB
(Inmazeb)Phase 3Biologic
RegeneronINMAZEB is one of 43 biologic programs targeting Prophylaxis. It is currently in Phase 3.
2
Indications
2
Total Trials
2
Active Trials
42
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
27 competitors in Prophylaxis
#DrugCompanyPhaseTrials
1Lovenox
SanofiApproved
Eliquis
Bristol-Myers SquibbApproved
Bayer Aspirin
BayerApproved
Cymbalta
Jazz PharmaceuticalsApproved
Coreg
Akero TherapeuticsApproved
Xarelto
WWim Janssens
Approved
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Cabenuva
GSKPhase 3
Lovenox
SanofiPhase 3
Prevymis
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Regulatory
FDA Approval Timeline[4]
Oct 14, 2020
INMAZEB
BLA BLA761169
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Inmazeb. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]